• Je něco špatně v tomto záznamu ?

Evidence of a vicious cycle in glutamine synthesis and breakdown in pathogenesis of hepatic encephalopathy-therapeutic perspectives

M. Holecek,

. 2014 ; 29 (1) : 9-17.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc15023634
E-zdroje Online Plný text

NLK ProQuest Central od 1999-01-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 2011-03-01 do Před 1 rokem
Health & Medicine (ProQuest) od 1999-01-01 do Před 1 rokem
Psychology Database (ProQuest) od 1999-01-01 do Před 1 rokem

There is substantial clinical and experimental evidence that ammonia is a major factor in the pathogenesis of hepatic encephalopathy. In the article is demonstrated that in hepatocellular dysfunction, ammonia detoxification to glutamine (GLN) in skeletal muscle, brain, and likely the lungs, is activated. In addition to ammonia detoxification, enhanced GLN production may exert beneficial effects on the immune system and gut barrier function. However, enhanced GLN synthesis may exert adverse effects in the brain (swelling of astrocytes or altered neurotransmission) and stimulate catabolism of branched-chain amino acids (BCAA; valine, leucine, and isoleucine) in skeletal muscle. Furthermore, the majority of GLN produced is released to the blood and catabolized in enterocytes and the kidneys to ammonia, which due to liver injury escapes detoxification to urea and appears in peripheral blood. As only one molecule of ammonia is detoxified in GLN synthesis whereas two molecules may appear in GLN breakdown, these events can be seen as a vicious cycle in which enhanced ammonia concentration activates synthesis of GLN leading to its subsequent catabolism and increase in ammonia levels in the blood. These alterations may explain why therapies targeted to intestinal bacteria have only a limited effect on ammonia levels in patients with liver failure and indicate the needs of new therapeutic strategies focused on GLN metabolism. It is demonstrated that each of the various treatment options targeting only one the of the ammonia-lowering mechanisms that affect GLN metabolism, such as enhancing GLN synthesis (BCAA), suppressing ammonia production from GLN breakdown (glutaminase inhibitors and alpha-ketoglutarate), and promoting GLN elimination (phenylbutyrate) exerts substantial adverse effects that can be avoided if their combination is tailored to the specific needs of each patient.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15023634
003      
CZ-PrNML
005      
20150729100847.0
007      
ta
008      
150709s2014 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s11011-013-9428-9 $2 doi
035    __
$a (PubMed)23996300
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Holecek, Milan $u Department of Physiology, Faculty of Medicine in Hradec Kralove, Charles University in Prague, Simkova 870, 500 38, Hradec Kralove, Czech Republic, holecek@lfhk.cuni.cz.
245    10
$a Evidence of a vicious cycle in glutamine synthesis and breakdown in pathogenesis of hepatic encephalopathy-therapeutic perspectives / $c M. Holecek,
520    9_
$a There is substantial clinical and experimental evidence that ammonia is a major factor in the pathogenesis of hepatic encephalopathy. In the article is demonstrated that in hepatocellular dysfunction, ammonia detoxification to glutamine (GLN) in skeletal muscle, brain, and likely the lungs, is activated. In addition to ammonia detoxification, enhanced GLN production may exert beneficial effects on the immune system and gut barrier function. However, enhanced GLN synthesis may exert adverse effects in the brain (swelling of astrocytes or altered neurotransmission) and stimulate catabolism of branched-chain amino acids (BCAA; valine, leucine, and isoleucine) in skeletal muscle. Furthermore, the majority of GLN produced is released to the blood and catabolized in enterocytes and the kidneys to ammonia, which due to liver injury escapes detoxification to urea and appears in peripheral blood. As only one molecule of ammonia is detoxified in GLN synthesis whereas two molecules may appear in GLN breakdown, these events can be seen as a vicious cycle in which enhanced ammonia concentration activates synthesis of GLN leading to its subsequent catabolism and increase in ammonia levels in the blood. These alterations may explain why therapies targeted to intestinal bacteria have only a limited effect on ammonia levels in patients with liver failure and indicate the needs of new therapeutic strategies focused on GLN metabolism. It is demonstrated that each of the various treatment options targeting only one the of the ammonia-lowering mechanisms that affect GLN metabolism, such as enhancing GLN synthesis (BCAA), suppressing ammonia production from GLN breakdown (glutaminase inhibitors and alpha-ketoglutarate), and promoting GLN elimination (phenylbutyrate) exerts substantial adverse effects that can be avoided if their combination is tailored to the specific needs of each patient.
650    _2
$a větvené aminokyseliny $x metabolismus $x terapeutické užití $7 D000597
650    _2
$a amoniak $x metabolismus $7 D000641
650    _2
$a mozek $x metabolismus $7 D001921
650    _2
$a kritický stav $7 D016638
650    _2
$a lékové interakce $7 D004347
650    _2
$a enterocyty $x metabolismus $7 D020895
650    _2
$a kyselina glutamová $x metabolismus $x farmakologie $x terapeutické užití $7 D018698
650    _2
$a glutaminasa $x antagonisté a inhibitory $7 D005972
650    _2
$a glutamin $x metabolismus $7 D005973
650    _2
$a jaterní encefalopatie $x dietoterapie $x farmakoterapie $x metabolismus $7 D006501
650    _2
$a lidé $7 D006801
650    _2
$a hyperamonemie $x farmakoterapie $x etiologie $x metabolismus $7 D022124
650    _2
$a střeva $x mikrobiologie $7 D007422
650    _2
$a kyseliny ketoglutarové $x škodlivé účinky $x farmakologie $x terapeutické užití $7 D007656
650    _2
$a ledviny $x metabolismus $7 D007668
650    _2
$a játra $x metabolismus $7 D008099
650    _2
$a mikrobiota $7 D064307
650    _2
$a kosterní svaly $x metabolismus $7 D018482
650    _2
$a orgánová specificita $7 D009928
650    _2
$a fenylbutyráty $x škodlivé účinky $x farmakologie $x terapeutické užití $7 D010654
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
773    0_
$w MED00007770 $t Metabolic brain disease $x 1573-7365 $g Roč. 29, č. 1 (2014), s. 9-17
856    41
$u https://pubmed.ncbi.nlm.nih.gov/23996300 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150709 $b ABA008
991    __
$a 20150729100933 $b ABA008
999    __
$a ok $b bmc $g 1083971 $s 906627
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 29 $c 1 $d 9-17 $i 1573-7365 $m Metabolic brain disease $n Metab Brain Dis $x MED00007770
LZP    __
$a Pubmed-20150709

Najít záznam

Citační ukazatele

Nahrávání dat ...

    Možnosti archivace